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SUMMARY
It has been suggested that the evolution of
vertebrate opioid receptors (ORs) follow a vector
of increased functionality. Here, we test this idea
by comparing human and frog ORs. Interestingly,
some of the most potent opioid peptides known
have been isolated from amphibian skin secretions.
Here we show that such peptides (dermorphin and
deltorphin) are highly potent in the human receptors
and inactive in frog ORs. The molecular basis for the
insensitivity of the frog ORs to these peptides was
studied using chimeras and molecular modeling.
The insensitivity of the delta OR (DOR) to deltorphin
was due to variation of a single amino acid, Trp7.35,
which is a leucine in mammalian DORs. Notably,
Trp7.35 is completely conserved in all known DOR
sequences from lamprey, fish, and amphibians.
The deltorphin-insensitive phenotype was verified
in fish. Our results provide a molecular explanation
for the species selectivity of skin-derived opioid
peptides.
INTRODUCTION
Opioid receptors (ORs) mediate the analgesic and antinocicep-
tive effects of endogenous opioid peptides and exogenous
opioid small molecules in vertebrates (Snyder and Pasternak,
2003; Stevens, 2009; Stevens and Newman, 1999). The three
classic ORs, designated mu, delta, and kappa (MOR, DOR,
and KOR), were originally characterized by the pharmacological
profiles of their responses to both shared and type-specific li-
gands (Snyder and Pasternak, 2003). The genes for these three
ORs, along with the related nociceptin receptor, occur on sepa-
rate chromosomes in most known vertebrate genomes (Snyder
and Pasternak, 2003; Stevens, 2009). Sequence-based studies
of ORs have suggested that these four ORs arose via two
genome-wide pre-Mesozoic duplication events (Stevens, 2009;
Dreborg et al., 2008; Prince and Pickett, 2002; Stevens et al.,
2007b; Sundstrom et al., 2010).
Early studies of the analgesic and antinociceptive effects of
opioid compounds in amphibians and fish provided evidence
for the existence of opioid-like receptors in these organisms
(Stevens and Newman, 1999; Stevens et al., 1994; Ehrensing
et al., 1982; Chervova et al., 1994; Sneddon, 2004; Jansen and
Greene, 1970), although these receptors differed pharmacolog-
ically from their mammalian orthologs. One of the first lines of ev-
idence for this was derived from studies of KOR-like sites in the
brain of the edible frog (Rana esculenta), in which it was reported
that the KOR-like binding sites had higher affinities for MOR- and
DOR-specific compounds than mammalian KOR receptors (Be-
nyhe et al., 1990a, 1990b). Intriguingly, the degree of stereose-
lectivity for arylacetamide and benzomorphan-derived ligands
was also less at frog KOR than at the mammalian receptors (Be-
nyhe et al., 1992).
All four ORs have subsequently been cloned from additional
amphibian and fish species (Stevens et al., 2007b; Darlison
et al., 1997; Barrallo et al., 1998, 2000; Rodriguez et al., 2000; Al-
varez et al., 2006; Bradford et al., 2005, 2006; Walthers et al.,
2005), and genome sequencing projects have revealed these
same receptors in a large number of other species. The se-
quences of the four types of ORs are highly conserved among
species, with themost striking differences between themamma-
lian and non-mammalian receptors being in the extracellular loop
domains (Stevens, 2009; Stevens et al., 2007b), regions consid-
ered to constitute the selectivity filter of ORs (Peeters et al., 2011;
Wheatley et al., 2012). In general, pharmacological studies have
revealed that ORs from mammals are more selective than those
from non-mammals (Bradford et al., 2005, 2006; Walthers et al.,
2005; Brasel et al., 2008), leading to the hypothesis that OR type
selectivity exhibits an evolutionary vector of increased selectivity
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from fish and amphibians to mammals (Stevens, 2009). Among
the many striking differences between the opioid systems of
mammals and amphibians is the presence of highly potent
endogenous opioid peptides (deltorphins [Erspamer et al.,
1989] and dermorphins [Montecucchi et al., 1981]) in the skin
of many amphibians and mollusks (Lazarus et al., 1999). Here,
we show that although opioid-like peptides from amphibian
epidermal secretions are remarkably potent at the human recep-
tors, they do not activate the frog receptors. Further, by using hu-
man-frog chimeric receptors, site-directed mutagenesis, and
molecular modeling of newly solved structures of OR-peptide
complexes, we established the molecular basis of these differ-
ences. Our results predicted that DORs from lamprey, fish, and
amphibian (LFA) sources would be insensitive to deltorphin,
and we confirmed this prediction by showing that they are inac-
tive in zebrafish in vivo.
RESULTS
Pharmacological Comparison of Human and Frog Opioid
Receptors
In preliminary experiments, we tested the expression levels of
three human (hKOR, hMOR, hDOR) and three frog (Rana pipiens;
rpKOR, rpMOR, rpDOR) ORs via saturation binding assays using
[3H]diprenorphine (see Experimental Procedures for details). All
transfected receptors displayed high-affinity [3H]diprenorphine
binding (KD values ranged from 0.6 to 2.2 nM), with high expres-
sion levels (Bmax ranged from 2 to 8 pmol/mg) (Table 1), facili-
tating the comparison of functional data between species.
We used a previously described Gai assay (Fenalti et al., 2014;
Vardy et al., 2013; White et al., 2014, 2015; Wu et al., 2012) to
characterize the differential selectivity profiles of R. pipiens
versus human ORs (Table 2). For these studies, we evaluated
the agonist potencies and efficacies of 14 agonists at each of
the three different ORs from R. pipiens and humans. In most
cases when comparing human and frog ORs, agonists main-
tained their type selectivity, albeit with lower potencies at the
frog receptors. Thus, for example, the delta-selective ligand DA-
DLE ([D-Ala2,D-Leu5]-enkephalin) was 90-fold less potent at the
frog than at the human DOR. Similarly, the mu-selective agonist
DAMGO ([D-Ala2,N-MePhe4,Gly-ol]-enkephalin) was 300-fold
less potent at the frog than at the human MOR. Interestingly,
the differences between frog and human receptors were less
pronounced when naturally occurring mammalian opioid pep-
tides were evaluated. Thus, for example, the endomorphins
were 20-fold less potent at the frog MOR than at the human
MOR. Interestingly, whereas all of the tested KOR-specific
peptides (dynorphin A, dynorphin B, and a-neoendorphin) were
10-fold less potent at the frog KOR, the amphibian dynorphin
xendorphin (Stevens et al., 2007a; Pattee et al., 2003) was
equally active at frog and human KORs. Type selectivity was
mostly maintained in frog relative to human ORs. However, in
the case of the synthetic peptides DADLE and DAMGO, type
selectivity differed between species (see Table 2 for details).
By contrast, the KOR-selective dynorphins, as well as the small
molecule salvinorin A, were similarly selective in human and
amphibian KORs.
The most pronounced differences between the human and
frog receptors were seen with the dermorphin and deltorphin
peptides, which are secreted in the skin of the tree frog Phyllo-
medusa bicolor. As previously documented, dermorphin is a
potent and selective human MOR agonist, and deltorphin II
and deltorphin C are potent and selective human DOR agonists.
Deltorphin II and deltorphin C were inactive at the three tested
frog ORs (Figure 2B; Table 2) while dermorphin was an exceed-
ingly weak agonist (Figure 2A; Table 2).
Identification of the Molecular Determinants of the
Pharmacological Differences between Frog and Human
Opioid Receptors
We next sought to determine the molecular basis for this striking
species selectivity. An analysis of the sequences of human and
frog receptors revealed that, for the most part, the major differ-
ences between these ORs reside in the extracellular loops and
the receptor termini (Stevens et al., 2007b) (Figure 1; Figure S1).
We hypothesized that the functional differences between human
and frog ORs stem from differences in their corresponding se-
quences. Therefore, to characterize the molecular basis for the
pharmacological differences between the frog and human
MORs and DORs, a series of chimeric receptors was made to
produce frog ORs with human inserts in various transmembrane
and extracellular domains (Figures 1B and 1C; Table S2),
covering most of the differences between the species, except
for the N and C termini. The chimeras were designed to explore
the idea that sequences in certain regions of the human recep-
tors may be critical for their increased sensitivity compared
with their frog homologs. The new chimeras and mutants
explored most of the differences between human and frog
ORs, except for the N and C termini.
Mu ORs
Four chimeras (1–4 in Figure 1B) were built, which swapped
single stretches of human MOR sequences into the frog
MOR. Functional analyses of the responses of these four
chimeras to endomorphin, dermorphin, or DAMGO showed
that their responses were essentially identical to the wild-type
frog MOR. Since the N terminus of the human MOR had
been implicated in the binding of opioid peptides (Bond
et al., 1998), we constructed three additional MOR chimeras
(5–7 in Figure 1B) by humanizing the N termini of three
constructs (residues 1–220 of wild-type [WT] rpMOR, rpMOR
Table 1. [3H]Diprenorphine Saturation Binding: Receptor Expression Levels (Bmax) and Affinity (KD) for Diprenorphine
KOR MOR DOR
Frog Human Frog Human Frog Human
Bmax (pmol/mg) 2 ± 0.2 2.6 ± 1.2 8.8 ± 1.3 2.2 ± 0.3 2.1 ± 0.3 5.7 ± 1.1
KD (nM) 1.2 ± 0.3 0.8 ± 0.6 2.2 ± 0.9 0.6 ± 0.2 0.8 ± 0.3 1.8 ± 0.9
Data from three separate experiments are expressed as mean ± SEM.
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EL2h, and rpMOR EL3h). These chimeras, h-rpMOR-WT,
h-rpMOR-EL2h, and h-rpMOR-EL3h, were more responsive
to the tested peptides than the WT rpMOR (Figure 2A; Table 3).
Moreover, the humanization of different regions had differential
effects on the responses to various peptides: the activity of
DAMGO, endomorphin 1, and endomorphin 2 in rpMOR was
partially rescued by humanization of the N terminus, and
even further enhanced by humanization of EL3h, but not
by EL2h (Table 3). Interestingly, the activity of dermorphin
with the chimeric MOR followed a different pattern (Table 3;
Figure 2A); humanization of the N terminus rescued receptor
activation by dermorphin, which was slightly enhanced
by humanization of EL3 (2-fold) and markedly enhanced by
humanization of EL2 (10-fold). We also examined the affinity
of DAMGO and dermorphin to these chimeras using a compe-
tition binding assay with radiolabeled diprenorphine (Figure 2A;
Table 3). Interestingly, the affinity of DAMGO was not altered
between the frog MOR and the three chimeras (Ki range 100–
200 nM), whereas the affinity of dermorphin to rpMOR was
increased by 30-fold only in the h-rpMOR EL2h chimera, an
effect that correlated well with the functional data.
Delta ORs
Five DOR chimeras (1–5 in Figure 1C), in which single stretches
of the frog DOR were humanized, were constructed and tested
by functional and binding studies with peptide ligands (Table
S3; Figure 2B). Changing TM4 or TM5 from the frog sequence
to the human sequence (1–3 in Figure 1C) slightly reduced the
activity of all four tested peptides, despite the fact that the
human WT receptor is more responsive to these ligands than
the frog WT receptor. Changing TM6 from frog to human (4 in
Figure 1C) slightly increased the potencies of all four peptides
(Table S3). Changing EL2 from frog to human increased the
potencies of DADLE and the deltorphins, but not enkephalin
(Table S3; Figure 2B). Changing EL3 from frog to human
increased the potencies and the affinities of all of the tested
peptides.
To further explore the role of the EL3 region in DOR activity,
we mutated several residues of interest in EL3 and the begin-
ning of TM7 of rpDOR to their corresponding human residues.
The mutants Met287Leu, Asn294Asp, and Tyr296Leu main-
tained the rpDOR phenotype, i.e., they did not respond to
deltorphin (data not shown), but the mutant Trp301Leu (7.35
in the numbering scheme of Ballesteros and Weinstein, 1995)
responded to deltorphin with substantially increased potency
and affinity compared with rpDOR; this mutation also partially
rescued activation by the other tested peptides (Table S3).
Structural Basis of the Role of W7.35 in Deltorphin
Selectivity
To evaluate the importance of position 7.35 inORs, we tested the
effect of the reverse mutation in the human DOR (Leu300Trp).
Significantly, the L300Wmutation diminished deltorphin potency
nearly 2000-fold (Figure 3C). Bioinformatics analysis of DORs
from multiple species reveals an interesting pattern: all of the
known sequences of DOR from LFA contain tryptophan at posi-
tion 7.35 (Figures 3A and 3B).
To elucidate a structural explanation for the role of W7.35, we
next performed docking studies of deltorphins into the WT
human DOR in complex with DIPP-NH2 tetrapeptide (PDB:
4RWD) (Fenalti et al., 2015) and to a modeled L3.75W mutation.T
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In this study, DIPP-NH2 peptide has been found to have weak
partial agonist activity at human (but not murine) DOR, although
this entails only minor changes in the receptor binding pocket
compared with the antagonist naltrindole bound DOR. There-
fore, the structure of DOR bound to a DIPP-NH2 can provide
information about the initial interaction between peptide ago-
nists and the receptor. Both deltorphin C and deltorphin II are
predicted to bind to the human DOR in similar binding poses,
characterized by several key interactions with the receptor
(Figure 4A–4C). Notably, the N-terminal amino group forms a
salt bridge with the Asp128(3.32) side-chain carboxylate group,
while the tyrosine aromatic ring occupies a hydrophobic core
pocket, with its hydroxyl group making polar interactions with
ordered waters found in high-resolution DOR structures. We
note that inclusion of these water molecules in the structural
model was important for consistently high-scoring docking of
the peptide. Residues 1–4 of the ligand backbone adopt a
well-defined turn conformation, which positions the D-Ala2 and
Figure 1. Sequence Divergence in ORs from
Frogs and Humans
(A) Crystal structures of the human KOR, DOR, and
MOR. Transmembrane domains are colored using
a color gradient from red (TM1) to blue (TM7); yel-
low regions are the receptor regions that differ
between human and frog receptors (for more de-
tails, see sequence alignments in Figure S1).
(B and C) Chimeras used in this study: rpDOR
chimeras (B, 1–5) and rpMOR chimeras (C, 1–7).
The chimeras were constructed by replacing re-
gions of rpOR (white with gray outline) with their
corresponding human sequences (black).
Phe3 side chains in hydrophobic sub-
pockets, and allows the acidic side chain
of Asp/Glu4 to extend back into the
pocket to form additional interactions
with the N-terminal amino group and the
Tyr56 side chain. Interestingly, free dynor-
phin peptides were predicted to preferen-
tially adopt a very similar conformation for
residues 1–4 in extensive energy optimi-
zations. The C-terminal residues 5–7 are
less defined in our docking, with several
possible low-energy conformations pre-
dicted for each peptide. Importantly, res-
idue 7.35 is positioned at the entrance to
the binding cavity, and Leu7.35 in the
human DOR comprises a part of the hy-
drophobic pocket that accommodates
the benzene ring of the peptide Phe3
(Fenalti et al., 2015). In the frog DOR, how-
ever, mutation to a more bulky Trp7.35
side chain results in a prominent steric
clash between its indole ring and Phe3
(Figure 4C). Attempts to dock deltorphins
to the hDOR(Leu7.35Trp) mutant and a
frog DOR model resulted in less consis-
tent ligand poses and degraded binding
scores. Taken together, these modeling
results support a prominent role for residue 7.35 as a selectivity
filter in DOR.
Zebrafish Are Insensitive to Deltorphin
The mutagenesis and bioinformatics results suggested that the
insensitivity of rpDOR to deltorphin was likely to be true of
DORs from most, if not all, LFA. To test this prediction, an inde-
pendent model system in which deltorphin affinity and potency
had never been tested was selected; to this end, we tested the
effect of DOR agonists on zebrafish swimming behavior. We
treated larvae, 7 days post fertilization (dpf), with deltorphin or
enkephalin peptides for 1 hr and quantified their swimming
behavior. When zebrafish were treated with either of the enkeph-
alin peptides, we observed dose-dependent decreases in swim-
ming levels. In contrast, the deltorphins had no significant effect
on zebrafish swimming (Figure 3D). We conclude that zebrafish
are specifically sensitive to the enkephalin peptides and not del-
torphins, likely due to the presence of W rather than L at position
7.35 of the zebrafish DOR.
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DISCUSSION
Themain finding of this study is that frog-derived opioid peptides
show remarkable species selectivity, which is specified—in the
case of DOR—by a single amino acid change that has been
conserved in all higher vertebrates. Clearly a functional compar-
ison of orthologous receptors from different species can facili-
tate our understanding of the relationship between structure
and function of these receptors; in addition, such comparisons
may help us to understand how these receptors evolved, and
the pressures that may have been exerted to promote such evo-
lution. In the current study, we have verified that all of the frog
and human receptors were functionally expressed in HEK293T
Figure 2. Molecular Basis for Dermorphin
and Deltorphin Insensitivity in rpORs
(A and B) Inhibition of isoproterenol (300 nM)
induced cAMP response and [3H]diprenorphine
competition in MOR variants by dermorphin and
DAMGO (hMOR , n = 4; rpMOR , n = 4;
h-rpMOR WT , h-rpMOR-EL2h , h-rpMOR-
EL3hA) (A) and in DOR variants by deltorphin and
DADLE (hDOR , n = 4; rpDOR , n = 4; rpDOR
EL2h , rpDOR-EL2h , rpDOR-EL3hC) (B). The
cAMP data presented are normalized data
collected from experiments done with triplicate
determinations for each point. n = 3 separate ex-
periments unless stated otherwise. The binding
isotherms are representative curves, the Ki values
are in Tables 3 and 4.
cells, and were coupled to Gai, as would
be predicted on the basis of sequence
identity in the intracellular loop regions
of ORs from frogs and humans. We
showed that, in most cases, human ORs
respond to both naturally occurring and
synthetic peptides with higher potencies
than ORs from R. pipiens. This is true in
all of the examined cases except for the
Xenopus laevis-derived peptide xendor-
phin, which demonstrated a comparable
KOR-specific activity in both human and
frog KOR, and very low to no activity at
MOR and DOR receptors. The KOR spec-
ificity of xendorphin has been previously
demonstrated by displacement of a KOR
radioligand from rat whole brain mem-
branes (Pattee et al., 2003).
The lower potencies observed for all of
the frog ORs (Table 2) are consistent with
previous reports characterizing other
cloned non-mammalian ORs, including
those from white suckerfish (Darlison
et al., 1997) and rough-skinned newt
(Bradford et al., 2006). However, in the
case of the Xenopus dynorphin, xendor-
phin, we observed that although frog re-
ceptors are not highly activated by
mammalian peptides, the human recep-
tors may be compatible with the amphibian peptides. Together,
these data support the concept of an evolutionary vector that
leads from receptors with low responsiveness (low potency) in
non-mammalian aquatic or amphibian vertebrates to those
with high responsiveness and selectivity in mammals.
One of the initial motivations for this work was the observation
that certain amphibians can secrete large quantities of extremely
potent psychoactive compounds and peptides from their skin
without apparent ill effects. It has been proposed that such se-
cretions serve to protect against predators in nature (Lazarus
et al., 1994; Lazarus and Attila, 1993), and in other cases it has
been shown that the evolution of such natural defensive and
survival strategies is often accompanied by resistance or
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insensitivity to certain natural materials (Jordt and Julius, 2002;
Rowe et al., 2013; Straight et al., 1976; Takacs et al., 2001,
2004). As we show here, the amphibian ORswe tested are insen-
sitive to deltorphin and dermorphin and, in the case of deltorphin,
this is due mainly to a difference in sequence at a single
conserved residue: leucine (mammalian) versus tryptophan
(LFA) at position 7.35. Recent structural studies of antagonist-
bound human MOR and DOR (Fenalti et al., 2014; Granier
et al., 2012; Manglik et al., 2012) show that residue 7.35
(Trp318 and Leu300, respectively) lies at the entrance to the
binding site and is likely to be a part of the receptor specificity
determinant (Fenalti et al., 2014; Granier et al., 2012; Manglik
et al., 2012; Filizola and Devi, 2013). The Leu7.35Trp mutation
in human DOR resulted in decreased affinity for some of the
DOR-specific ligands (Pepin et al., 1997), whereas mutations of
the conserved tryptophan in MOR suggested the key role of
this residue for MOR specificity (Bonner et al., 2000; Xu et al.,
1999). As opioid-like peptides from frog skin are thought to be
a natural defense mechanism (Lazarus et al., 1994; Lazarus
and Attila, 1993), it would thus be advantageous for frogs that
these peptides are inactive, although one would expect them
to activate the receptors of potential frog predators.
A comparison of the structures of human DOR and MOR
(Fenalti et al., 2014; Granier et al., 2012; Manglik et al., 2012; Fil-
izola and Devi, 2013) revealed that there are 14 residues within
4 A˚ of the bound ligand, 11 of which are identical between the
two receptors; the three differences are at positions (in MOR)
Glu229 (in EL2), Lys303 (6.58), and Trp318 (7.35), which are
Asp, Trp, and Leu, respectively, in DOR. The substitution of
leucine for tryptophan in DOR at position 7.35 is responsible
for the binding selectivity both of the DOR-selective antagonist
naltrindole and the conformationally constrained DOR-selective
peptide agonist [D-Pen2-D-Pen5]enkephalin (DPDPE) (Pepin
et al., 1997). In addition, the Trp318Leu (7.35)mutation increased
the affinity of both of these ligands at MOR (Ulens et al., 2000).
Our conformational modeling studies of the hDOR-deltorphin
complexes also suggest that position 7.35 is the key position
in the binding pocket that defines the difference in selectivity be-
tween human and frog receptors. In the human DOR, both del-
torphin C and deltorphin II are predicted to bind with their
Phe3 side chain optimally positioned in a hydrophobic pocket
formed by Leu300(7.35), Val281(6.55), and Trp284(6.58), making
a pi-stacking interaction with the latter. In the frog DOR, the Trp
at position 7.35 narrows the binding pocket, and results in a
severe steric clash with Phe3 of the deltorphin peptide that pre-
cludes optimal ligand binding. Note that the conformation of the
mutant Trp7.35 in frog DOR is stabilized by contacts with nearby
residues, such as a stacking interaction with Trp6.58, precluding
optimal adjustment of the pocket and hampering accommoda-
tion of deltorphins. Two other non-conserved residues of DOR,
Val197 (Thr in frog) and Arg190 (Lys in frog) in the ECL2 are in
close proximity to the docked deltorphin, and may interact with
the ligand; however, such contacts in the more flexible and sol-
vent-exposed part of the ligand are not predicted to significantly
contribute to selectivity. This is in agreement with the observa-
tion that the Leu7.35Trp mutation in frog DOR almost completely
rescues deltorphin binding, while the opposite mutation in the
human receptor nearly eliminates deltorphin binding.
The molecular basis for the species selectivity of MOR-spe-
cific opioid-like peptides from frog skin was also studied using
chimeric receptors. The MOR-specific peptides tested in the
current study were consistently more potent at the human
MOR than at the frog MOR. The sequences of the human and
frog MORs differ in four regions, excluding the N and C termini.
In studies using chimeric receptors, there was little or no effect
of replacement of regions of the frog MOR with the human
sequence, unless the N terminus of the frog MOR was also re-
placed by the human sequence (5–7 in Figure 1B). This was
not surprising, since the N termini of these two receptors differ
markedly, and since the N terminus of MOR has been shown
to be critical for ligand binding (Chaturvedi et al., 2000). Once
the N termini had been swapped, the results showed that the hu-
man EL3 was important for receptor activation by all of the stud-
ied peptides (Table 3), and that the human EL2 had only a small
effect on activation, except for dermorphin (Table 3; Figure 2A).
Thus EL2, along with the N terminus, may be considered to be a
specificity determinant for dermorphin at MOR. The binding of
DAMGO and dermorphin to the rpMOR chimeras correlated
well with the response of the chimeric receptors in the functional
assays; however, there is a discrepancy between the binding
and function of DAMGO and dermorphin in WT rpMOR. DAMGO
and dermorphin are at least 100-fold less potent in rpMOR than
in any of the h-rpMOR chimeras, but both peptides bind to
rpMOR with affinity that is only slightly lower than that of
h-rpMOR-WT and h-rpMOR-EL3h (Figure 2A). This phenomenon
cannot be attributed to low expression levels, since we have
Table 3. Effect of Chimeras with Humanized N Terminus on the Function of rpMOR
hMOR rpMOR h-rpMOR-wt h-rpMOR-E2h h-rpMOR-E3h
DAMGO 10 (7.98 ± 0.08) 1,900 (5.71 ± 0.2) 96 (7.02 ± 0.08) 80 (7.09 ± 0.07) 22 (7.65 ± 0.07)
Ki = 21 ± 8 nM Ki = 135 ± 32 nM Ki = 250 ± 120 nM Ki = 122 ± 34 nM Ki = 490 ± 180 nM
Dermorphin 6 (8.23 ± 0.07) NA 230 (6.65 ± 0.08) 40 (7.40 ± 0.07) 130 (6.88 ± 0.1)
Ki = 28± 5.7 nM Ki = 1,800 ± 690 nM Ki = 1,700 ± 370 nM Ki = 160 ± 44 nM Ki = 7,800 ± 1,600 nM
Endomorphin 1 14 (7.85 ± 0.08) 360 (6.44 ± 0.1) 43 (7.36 ± 0.07) 95 (7.02 ± 0.06) 14 (7.85 ± 0.06)
Endomorphin 2 62 (7.21 ± 0.08) 920 (6.03 ± 0.12) 93 (7.03 ± 0.27) 190 (6.72 ± 0.32) 32 (7.50 ± 0.31)
Dynorphin A 1,300 (5.87 ± 0.16) 5,100 (5.29 ± 0.14) 1,300 (5.88 ± 0.27) 2,500 (5.59 ± 0.17) 520 (6.28 ± 0.22)
Activation of chimeric MOR variants by different opioid peptides was measured by inhibition of isoproterenol-stimulated cAMP response in HEK293T
cells. Ligand potency is presented along with affinity in selected receptor-ligand combinations. EC50 values (EC50 (nM) and logEC50 [M] ± SEM) were
derived from curve fitting of the normalized data from three experiments done in triplicate. Ki values are presented as the average ± SD taken from two
experiments. NA, not active.
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established comparable expression levels of human and frog re-
ceptors in HEK293T cells (Table 1). It is conceivable that the
N terminus of MOR is involved in signaling or trafficking of the re-
ceptor, thus resulting in lower apparent receptor activity. The
data presented here suggest that the low response of rpMOR
to dermorphin and other peptides originates in the N-terminal re-
gion and in EL2.
The functional and binding data of the frog DOR and its hu-
manized variants is more internally consistent than in the case
of MOR, i.e., a lower potency is reflected in a lower binding affin-
ity. In this case, we discovered that the EL3 of the frog DOR has
an important role in its deltorphin-insensitive phenotype. Further
analysis led to the discovery that Trp301(7.35) of the frog DOR is
the critical residue for insensitivity to deltorphin (Figure 2B;
Table 3). This notion was further supported by an analysis of
the reverse mutation in the human receptor, Leu300Trp. The
data in Figures 2B and 3C demonstrate that Leu300(7.35) is a
critical residue for activation of hDOR by DOR-specific agonists,
especially in the case of the Phyllomedusa-derived peptide del-
torphin (Figure 4). Phylogenetic analysis of DOR orthologs re-
vealed that all of the available sequences from LFA contain a
tryptophan at position 7.35 (Figures 3A and 3B). Together, these
data lead to the prediction that LFA are deltorphin insensitive.
This distinct functional difference between DORs from terrestrial
vertebrates and non-mammalian aquatic vertebrates and am-
phibians (LFA) leads to a hypothesis that the increased sensitivity
and selectivity of DOR have evolved, andmaintained, after diver-
gence of amphibians and mammalians.
To test this aquatic deltorphin insensitivity hypothesis, we
chose the zebrafishmodel system as an independent model; un-
like enkephalins, deltorphins did not have any effect in the zebra-
fish swimming assay. It is important to note that binding assays
done with R. pipiens tissue demonstrated that the affinities of
deltorphin and dermorphin to ORs in the brains and spinal cord
are very low (30–80 mM) (Newman et al., 2000a, 2000b) and,
although these peptides have been suggested to have some
in vivo effects in R. pipiens (Stevens, 1996), it seems unlikely
that these results are due to interactions with ORs, as they do
not bind to them with a pharmacologically relevant affinity.
The skin secretions of frogs, toads, and other amphibians
contain a multitude of psychoactive compounds to which they
maynotbesensitive.Here this concept isdemonstrated foropioid
peptides, and itmay also be the case for other psychoactive alka-
loidsandpeptides secretedbyamphibians. Theskin secretionsof
the toad Bufo alvarius contain, among other substances, the
psychoactive compounds 5-Me-DMT and 5-OH-DMT; these
compounds primarily target serotonin receptors and can
generate different serotonin-like effects, including hallucinations
(Fabing and Hawkins, 1956). Bombesin, bradykinin, and tachyki-
nin peptides are also found in the skin secretions of amphibians
(Lazarus andAttila, 1993), andwehypothesize that the amphibian
orthologs of the receptors for these compounds are likely to be
insensitive to them. We are currently testing this hypothesis with
a large number of other amphibian GPCR-skin secretants to
determine whether there is a generalized mechanism for this
insensitivity related to differential receptor sensitivity.
It is interesting to consider the evolutionary advantages of
these systems. Thus, for evolutionary success, the molecular
structure of toxin target sites (e.g., receptors) should beT
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conserved in a phylogenetically wide spectrum of taxa (Takacs
et al., 2001). Toxin inactivation or receptor insensitivity seems
to be related to the development of such poisons. How ORs
and opioid-like peptides might have evolved in frogs remains a
matter for speculation, although our data suggest that FLAmain-
tained the deltorphin-insensitive phenotype (Trp at position 7.35)
even though there is no evidence that they secrete or come into
contact with deltorphins in their natural habitats (Stevens and
Yaksh, 1986). Phyllomedusa spp. (the source of the skin pep-
tides) are considered by amphibian biologists the newest frog
species (Hillis et al., 1993; Inger, 1967), suggesting that these
peptides are a more recent evolutionary trait. Together, these
data suggest that the lower type selectivity hypothesized for
ORs in FLA might have been important for the ability of later
amphibian species to develop the highly potent opioid-like pep-
tides in their skin secretions.
SIGNIFICANCE
Comparative pharmacology is useful for exploring questions
related to structure-function relationship and evolutionary
mechanisms. Profound pharmacological distinctions along
Figure 3. Position 7.35 in DOR Is the Selectivity Filter
(A) Comparison of DOR EL3-TM7 sequence from different species highlighting position 7.35 with green (L) and red (W).
(B) Phylogenetic tree of vertebrate DORs (full sequence). DOR from terrestrial vertebrates (yellow background) contains leucine at position 7.35 and DOR from
non-terrestrial vertebrates (green background) contains tryptophan at position 7.35.
(C) The effect of tryptophan at position 7.35 in human DOR. Inhibition of cAMP response by three peptides in cells expressing hDOR or hDOR Leu300Trp.
(D) Zebrafish are sensitive to enkephalins but not deltorphins. Zebrafish larvae (7 dpf) were treated with increasing concentrations of DOR peptide ligands for 1 hr
and assayed for normal swimming activity. Results represent average motion ± SEM from 12 replicate wells of ten fish each, normalized to the vehicle (DMSO)
control. Statistical analysis was performed using Student’s t test (two-tailed, unpaired, unequal variance). Significance was determined as *p < 0.05, **p < 0.01.
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with a well-defined sequence differences between human
and frog receptors allowed the identification of the molecu-
lar basis for an interesting evolutionary phenomenon. It has
been previously suggested that the evolution of vertebrate
ORs followed a vector of increasing type selectivity; our re-
sults support this idea and show that as a general rule opioid
peptides activate human receptors to a higher degree than
the frog receptors, and the tested peptides exhibited
increased type selectivity in the human receptors relative
to the frog receptors. Interestingly, some of the most potent
opioid peptides known have been isolated from amphibian
skin secretions. Here, we show that such peptides (dermor-
phin and deltorphin), while highly potent in the human recep-
tors, are inactive in frog ORs. The molecular basis for the
insensitivity of the frog ORs to these peptides was studied
using chimeras and molecular modeling. While the molecu-
lar mechanism for the insensitivity was not completely
resolved due to its complexity, the DOR insensitivity to del-
torphin was shown to be due to variation of a single amino
acid, Trp7.35, which is a Leu in mammalian DORs. Notably,
Trp7.35 is completely conserved in all known DOR se-
quences from LFA. The deltorphin-insensitive phenotype
was verified in zebrafish. Our results provide a molecular
explanation for the species selectivity of skin-derived opioid
peptides, and raise an interesting discussion on the poten-
tial part that the low selectivity of frog ORs might have had
in the development of such peptides.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection
Human embryonic kidney (HEK) 293T cellsweremaintained inDMEM (Corning)
supplemented with 10% fetal bovine serum, 10 U/ml penicillin, and 10 mg/ml
streptomycin (Gibco). The cells were grown in a humidified incubator in the
presence of 5% CO2 at 37
C. Transient transfection (48 hr) of WT, chimeric,
Figure 4. Structural Model of Deltorphin
and DOR
(A) Surface representation of the binding pocket
(cyan) of the DOR and the docked position of
deltorphin C (orange). Roman numerals I–VII refer
to transmembrane domains 1–7, respectively.
ECL, extracellular loop.
(B and C) A Trp at position 7.35 of the hDOR
Leu300Trp mutant protrudes into the binding
pocket and narrows the entrance to the binding
pocket. Deltorphin C (orange carbon atoms) and
deltorphin II (yellow carbon atoms), docked into
hDOR structure are shown in stick presentation.
The Trp7.35 side chain in rpDOR (shown with
magenta carbons in both stick and transparent
sphere presentation) clashes with deltorphin pep-
tides and can occlude their binding.
and mutant receptor cDNAs was performed in
15-cm tissue culture plates using an optimized cal-
cium phosphate method (Jordan et al., 1996).
Construction of Chimeric and Mutant
Receptors
Human OR cDNAs in the mammalian expression
vector pcDNA3.1(+) (Invitrogen) were obtained
from the UMR cDNA Resource Center (http://www.cdna.org). Opioid recep-
tors from R. pipiens had previously been subcloned into the same vector
(Stevens et al., 2007b). Site-directed mutagenesis was done using the
QuikChange II mutagenesis kit (Agilent) according to the manufacturer’s in-
structions, and all mutations were confirmed by full-length automated DNA
sequencing (Eton Bioscience).
Generation of inter-species MOR and DOR chimeras was done using a two-
step overlap PCR method, as previously described (Vortherms et al., 2007),
and as illustrated in Figure S2. The sequences of all primers used are
given in Table S1. A total of five DOR chimeras (Figure 1C) and sevenMOR chi-
meras (Figure 1B) were made by humanizing regions of the frog receptors (i.e.,
replacing stretches of residues from the frog receptors with their human
counterparts).
In Vitro Characterization of OR Activation
Radioligand Binding Assay
Radioligand binding assays were performed as previously detailed (Yan et al.,
2005) using [3H]diprenorphine (PerkinElmer) for saturation binding assays
(10–0.1 nM), with 10 mM unlabeled naltrexone (Sigma) to determine non-spe-
cific binding.
Functional Assay
Inhibition of cAMP production was measured using the genetically encoded
cAMP biosensor, Glosensor-22F (Promega) as previously described (Allen
et al., 2011).
Modeling of DOR-Deltorphin Interactions
Docking of opioid peptides was performed with the hDOR structure recently
solved in complex with DIPP-NH2 peptide at 2.5 A˚ resolution (PDB: 4RWD)
(Fenalti et al., 2015). The receptor model was protonated and prepared using
an ICM docking pipeline. Three models were tested, one with all 23 water mol-
ecules retained from the crystal structure, one without waters, and one with
only the three water molecules mediating ligand interactions in hDOR-DIPP-
NH2 retained. These three waters were also found to be conserved among
the structures of different OR types.
Fully flexible models of the heptapeptides deltorphin C (Tyr-D-Ala-Phe-Asp-
Val-Val-Gly-NH2) and deltorphin II (Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2) were
docked into the hDOR model using the ICM energy-based docking algorithm,
which takes advantage of the internal molecular coordinates of the ligand. A
setting of thoroughness = 30 was used to ensure exhaustive sampling of the
peptide conformational space within the binding pocket. A large docking
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box (253 253 25 A˚) was used to ensure that it completely covered the peptide
binding pocket and the extracellular entrance of the receptor.
Ligand poses with the best binding scores were clustered and further
analyzed using all-atom optimization with side-chain flexibility in the ligand
binding pocket. Final energy-based binding scores were calculated using
the ICM scoring algorithm. The mutation Leu7.35Trp was introduced by re-
placing the Leu7.35 side chain with the Trp side chain in ICM, followed by
thorough energy-based optimization of the adjacent residues. The peptides
were docked in the mutated receptor, and binding scores calculated. In
addition, the conformational preferences of the free deltorphin peptides in
solvent were studied using exhaustive sampling of their rotamers, and the
resulting low-energy conformations were compared with the docked
deltorphins.
In Vivo Activity of DOR Agonists in Zebrafish
Aquaculture
We collected fertilized eggs from group matings of Ekkwill strain zebrafish
(Ekkwill Waterlife Resources). Embryos were raised in HEPES (10 mM,
pH 7.2) buffered E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and
0.33 mM MgSO4) on a normal 14/10-hr on/off light cycle at 28
C. At 3 dpf,
chorion debris was removed and larvae were transferred into fresh medium
until 7 dpf. At 7 dpf, larvae were counted and manually pipetted, ten larvae
per well, into clear 96-well, U-bottomed plates (250 ml/well) in the same
medium.
Peptide Treatment
All peptides were dissolved in DMSO, diluted to a 1003 concentration, and
added directly to zebrafish medium in 96-well plates (2.5 ml in 250 ml). Wells
were mixed and allowed to incubate for 1 hr at 28C in ambient light prior to
behavioral evaluation. The final DMSO concentration was 1%.
Swimming Assay
96-Well plates were loaded into a ZebraBox containing a computer-controlled
light box and a video camera with an infrared filter (ViewPoint Life Sciences).
Infrared light was used to illuminate the chamber, and the temperature was
maintained at 28C for the duration of the experiment. White light stimulation
was automated using ZebraLab software (ViewPoint Life Sciences) as follows:
dark for minutes 1, 3, 5, and 7; light for minutes 2, 4, and 6. At this age, dark-
ness stimulates swimming in fish (Burgess and Granato, 2007). Locomotor ac-
tivity was recorded during the dark phases by an infrared camera using the
ZebraLab Videotrack quantization mode at 30 frames/s. 96 evenly spaced re-
gions of equal size were drawn around each well of the assay plate using the
Viewpoint software. The software tracks the change in pixel intensity for each
region over time to produce a motion index, which correlates with the overall
amount of motion in the well. Each video was saved for review, and the data
were further analyzed using custom R scripts. We used a Student t test
(two-tailed, unpaired, unequal variance) to analyze motion index values. An
effect was considered significant at p < 0.05. All zebrafish protocols were
approved by the Institutional Animal Care and Use Committee at Massachu-
setts General Hospital.
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